<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938352</url>
  </required_header>
  <id_info>
    <org_study_id>CR102595</org_study_id>
    <secondary_id>CRU-CS-001</secondary_id>
    <secondary_id>CR8020FLZ2002</secondary_id>
    <secondary_id>2013-002185-39</secondary_id>
    <nct_id>NCT01938352</nct_id>
  </id_info>
  <brief_title>Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge</brief_title>
  <official_title>Randomised, Double-Blind, Placebo-Controlled, Phase IIa Study in Healthy Volunteers to Evaluate the Protective Efficacy and Safety of CR8020 in an Influenza Challenge Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Retroscreen Virology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      After prophylactic vaccination with CR8020, a monoclonal antibody, subjects will be&#xD;
      challenged with the H3N2 virus. The protective efficacy, safety, tolerability,&#xD;
      pharmacokinetics, and potential immunogenicity will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2013</start_date>
  <completion_date type="Actual">January 22, 2014</completion_date>
  <primary_completion_date type="Actual">January 22, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of viral load</measure>
    <time_frame>Day 7</time_frame>
    <description>Measured from the nasopharyngeal mucosa (by qPCR) post influenza virus challenge</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>CR8020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CR8020 administered as a single 2-hour intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a single 2-hour intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CR8020</intervention_name>
    <description>CR8020 15 mg/kg, administered by intravenous infusion</description>
    <arm_group_label>CR8020</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (hydrous dextrose in water for injection), administered by intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects ≥ 18 and ≤ 45 years of age.&#xD;
&#xD;
          2. In good health, with no major medical conditions from medical history, physical&#xD;
             examination, and routine laboratory tests as determined by the Investigator at a&#xD;
             screening evaluation.&#xD;
&#xD;
          3. A total body weight ≥50 kg and a BMI of &gt;18. If the BMI is above 28 the subject may be&#xD;
             included if the waist measurement is less than 94 cm (male), or less than 80 cm&#xD;
             (female).&#xD;
&#xD;
          4. (a) Male subjects must use highly effective contraception consisting of two forms of&#xD;
             birth control (one of which must be a barrier method) starting at entry to Quarantine&#xD;
             until after the Day 96 (± 5 days) Follow-up Visit.&#xD;
&#xD;
             (b) In addition, male subjects must not donate sperm following discharge from&#xD;
             Quarantine until after the Day 96 (± 5 days) Follow-up Visit.&#xD;
&#xD;
             (c) Female subjects must be either:&#xD;
&#xD;
               -  Documented status as surgically sterile or post hysterectomy or-&#xD;
&#xD;
               -  If of childbearing potential, must have a negative serum and urine pregnancy test&#xD;
                  at study specific screening and Day -4/-3 and must be using highly effective&#xD;
                  contraception consisting of two forms of birth control (one of which must be a&#xD;
                  barrier method) starting at entry to Quarantine and continue until the Day 96 (±&#xD;
                  5 days) Follow-up Visit.&#xD;
&#xD;
             Acceptable forms of effective contraception include:&#xD;
&#xD;
               -  Established use of oral, injected or implanted hormonal methods of contraception&#xD;
&#xD;
               -  Placement of an intrauterine device (IUD) or intrauterine system (IUS).&#xD;
&#xD;
               -  Barrier methods of contraception: Condom or occlusive cap (diaphragm or&#xD;
                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.&#xD;
&#xD;
               -  Male sterilisation (with the appropriate post-vasectomy documentation of the&#xD;
                  absence of sperm in the ejaculate). [For female subjects on the study, the&#xD;
                  vasectomised male partner should be the sole partner for that subject].&#xD;
&#xD;
             True abstinence: When this is in line with the preferred and usual lifestyle of the&#xD;
             subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
             post-ovulation methods) and withdrawal are not acceptable methods of contraception].&#xD;
&#xD;
          5. An informed consent document signed and dated by the subject and Investigator.&#xD;
&#xD;
          6. Sero-suitable for challenge virus.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have a significant history of tobacco use at any time (≥ total 10 pack&#xD;
             year history, e.g. one pack a day for 10 years)&#xD;
&#xD;
          2. (a) Females who are pregnant or have been pregnant within six months prior to the&#xD;
             study, or who have been breastfeeding within three months prior to screening. Females&#xD;
             who have a positive pregnancy test at any point in the study will be withdrawn&#xD;
             immediately.&#xD;
&#xD;
             (b) Females intending to become pregnant within three months of administration of&#xD;
             CR8020 or placebo or males with female partners intending to become pregnant within&#xD;
             three months of administration of CR8020 or placebo&#xD;
&#xD;
          3. Any history or evidence of any clinically significant cardiovascular,&#xD;
             gastrointestinal, endocrinological, haematological, hepatic, immunological, metabolic,&#xD;
             urological, neurological, psychiatric, renal, and/or other major disease or&#xD;
             malignancy, as judged by the Investigator&#xD;
&#xD;
               1. Eczema/Atopic Dermatitis: (Subjects with clinically mild eczema/atopic dermatitis&#xD;
                  may be included at the Investigator's discretion e.g. if there is no regular use&#xD;
                  of topical steroids, no eczema in cubital fossa)&#xD;
&#xD;
               2. Psoriasis:(Subjects with active psoriasis affecting less than 5% of the body's&#xD;
                  surface area for the past five years can be included at the Investigator's&#xD;
                  discretion- (1% of the body area is roughly equivalent to the palm of the&#xD;
                  subject's hand). Patients with a history of completely resolved guttate psoriasis&#xD;
                  can be included)&#xD;
&#xD;
               3. Psychiatric: (Subjects with a diagnosis of a single mild or moderate depressive&#xD;
                  episode two or more years ago, with good evidence of preceding stressors and&#xD;
                  which resolved within approximately three months (i.e. reactive depression), may&#xD;
                  be included at the Investigator's discretion)&#xD;
&#xD;
          4. Abnormal pulmonary function in the opinion of the Investigator as evidenced by&#xD;
             clinically significant abnormalities on spirometry&#xD;
&#xD;
          5. History or evidence of autoimmune disease or known immunodeficiency of any cause&#xD;
&#xD;
          6. Subjects with any history of asthma, chronic obstructive pulmonary disease (COPD),&#xD;
             pulmonary hypertension, reactive airway disease, or chronic lung condition of any&#xD;
             aetiology (See No. 7 for asthma)&#xD;
&#xD;
          7. Asthma (A history of childhood asthma before the age of 12 is acceptable provided the&#xD;
             subject is asymptomatic without treatment. Patients with a single episode of wheezing&#xD;
             after age 12 (lasting less than eight weeks) can be included at the Investigator's&#xD;
             discretion)&#xD;
&#xD;
          8. Positive human immunodeficiency virus (HIV), Hepatitis A (HAV), B (HBV), or C (HCV)&#xD;
             test&#xD;
&#xD;
          9. Any significant abnormality altering the anatomy of the nose or nasopharynx&#xD;
&#xD;
         10. Any clinically significant history of epistaxis&#xD;
&#xD;
         11. Any nasal or sinus surgery within six months of Viral Challenge&#xD;
&#xD;
         12. Recurrent history of clinically significant autonomic dysfunction&#xD;
&#xD;
         13. Any abnormal laboratory test or ECG which is deemed by the Investigator to be&#xD;
             clinically significant&#xD;
&#xD;
         14. Confirmed positive test for drugs of abuse deemed by the Investigator to be clinically&#xD;
             significant&#xD;
&#xD;
         15. Venous access deemed inadequate for the phlebotomy and cannulation demands of the&#xD;
             study&#xD;
&#xD;
         16. Known allergy to any of the following:&#xD;
&#xD;
               -  excipients in the Challenge Virus inoculum&#xD;
&#xD;
               -  any CR8020 excipients (sucrose, L-histidine L-histidine monohydrochloride,&#xD;
                  polysorbate 20)&#xD;
&#xD;
               -  oseltamivir or other influenza treatments&#xD;
&#xD;
         17. Health care workers (e.g. doctors, nurses, medical students and allied healthcare&#xD;
             professionals) who work in units with severely immuno-compromised patients (e.g. bone&#xD;
             marrow transplant units)&#xD;
&#xD;
         18. Presence of household member or close contact(s) (for an additional two weeks after&#xD;
             discharge from the isolation facility) who:&#xD;
&#xD;
               -  has known immunodeficiency&#xD;
&#xD;
               -  is receiving immunosuppressant medication&#xD;
&#xD;
               -  is undergoing or soon to undergo cancer chemotherapy within 28 days of Viral&#xD;
                  Challenge&#xD;
&#xD;
               -  has been diagnosed with emphysema, COPD, or other severe lung disease and resides&#xD;
                  in a nursing home&#xD;
&#xD;
               -  has received a bone marrow or solid organ transplant&#xD;
&#xD;
         19. Evidence of vaccinations within the four weeks prior to Human Viral Challenge.&#xD;
             Intention to receive travel vaccination(s) before the Day 96 (± 5 days) Follow Up&#xD;
             Visit&#xD;
&#xD;
         20. Those employed or immediate relatives of those employed at Retroscreen Virology&#xD;
             Limited or the Sponsor&#xD;
&#xD;
         21. Receipt of blood or blood products, or loss (including blood donations) of 450 mL or&#xD;
             more of blood, during the three months prior to Viral Challenge or planned&#xD;
             donation/receipt throughout the course of the study&#xD;
&#xD;
         22. Use of nasal steroids within 28 days prior to Viral Challenge Use of any other&#xD;
             medication or product (prescription or over-the-counter), for symptoms of hay fever,&#xD;
             rhinitis, nasal congestion or respiratory tract infection within seven days of Viral&#xD;
             Challenge&#xD;
&#xD;
         23. Receipt of any investigational drug within three months prior to Viral Challenge Prior&#xD;
             participation in a clinical trial with the same strain of respiratory virus&#xD;
             Participation in any other Human Viral Challenge study with a respiratory virus within&#xD;
             one year prior to the day of Viral Challenge&#xD;
&#xD;
         24. Receipt of systemic glucocorticoids, antiviral drugs, or immunoglobulins (Igs) or any&#xD;
             other cytotoxic or immunosuppressive drug within six months prior to dosing, or&#xD;
             receipt or any systemic chemotherapeutic agent at any time&#xD;
&#xD;
         25. Previous receipt of monoclonal antibodies or monoclonal antibody fragments at any time&#xD;
&#xD;
         26. Presence of significant respiratory symptoms existing on the day of challenge or&#xD;
             between admission to the unit and inoculation with the Challenge Virus History&#xD;
             suggestive of respiratory infection within 14 days prior to admission to the&#xD;
             Quarantine Unit&#xD;
&#xD;
         27. Any other finding that, in the opinion of the Investigator or Sponsor, deems the&#xD;
             subject unsuitable for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Virus</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Immunization</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

